Novel approach to overcome malignant cancer by targeting Y-box binding protein-1(YB-1)

HER2过表达是胃癌患者预后不良的预测因素。目前，her2靶向抗体曲妥珠单抗已经提高了治疗her2阳性晚期胃癌的疗效。本研究表明，Y-box binding protein-1 （YB-1）敲低可抑制HER2的表达，影响胃癌细胞对EGFR和HER2双激酶抑制剂拉帕替尼的耐药性。此外，在人胃癌中，细胞核中YB-1的表达也与HER2的表达特异性相关。因此，YB-1-HER2轴可以促进her2靶向药物治疗胃癌的个性化治疗的进一步发展。

HER2 overexpression is a predictive factor of poor prognosis in patients with gastric cancer. Currently, the HER2-targeted antibody, trastuzumab, has improved the efficacy of therapy for HER2-positive advanced stomach cancer. This study demonstrated that Y-box binding protein-1 (YB-1) knockdown suppressed the expression of HER2, affecting drug resistance to lapatinib, a dual kinase inhibitor of EGFR and HER2, in gastric cancer cells. Moreover, nuclear YB-1 expression was also specifically correlated with expression of HER2 in human gastric cancer. YB-1-HER2 axis could thus contribute to further development of personalized therapeutics by HER2-targeted drugs against gastric cancer.